Swedish Orphan Biovitrum AB (publ) SOBI
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position may be maintained at current valuation.
Strong growth, pipeline progress and new NTAP status for Gamifant outweigh leverage and regulatory risks, supporting the HOLD signal.
The market reacts positively to strong earnings growth, pipeline progress and the new NTAP status for Gamifant despite some uncertainty around the CEO change.
HOLD is the call. Positive is the market mood. Low risk means less can go wrong.
Latest change
- 21 Aug 2026 — ▲ Risk score fell from 8 to 4 following strong Q2 growth and raised full-year guidance that reduced uncertainty around debt and regulatory delays.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (7) — follow the company freeAbout the company
Swedish Orphan Biovitrum develops and commercializes medicines in hematology and immunology. The company shows strong growth driven by products such as Altuvoct, Doptelet and Gamifant. Operations are profitable with positive cash flow generation.
Bull case
Strong Q2 growth, raised full-year guidance and NTAP for Gamifant provide momentum around pipeline progress.
Bear case
High net debt after acquisitions and regulatory delays for NASP create uncertainty.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| Altuvoct sales | Lower than expected growth → 2026 revenue forecast at risk of being missed. | Stronger sales → higher EBITA margin and raised guidance. |
| NASP approval | Further delays → postponed revenues from gout treatment. | Rapid approval → new revenue stream from 2027. |
Why this signal
Strong growth, pipeline progress and new NTAP status for Gamifant outweigh leverage and regulatory risks, supporting the HOLD signal.
Recent news
Q2 report showed 29% growth and raised guidance. Innate Pharma licensing agreement became effective in September with USD 75M upfront. FDA granted Fast Track status for pacritinib in VEXAS syndrome. Arctic Securities initiated coverage with Buy rating and SEK 551 target. CMS granted NTAP for Gamifant. CEO Guido Oelkers announced departure in early 2027.